Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: Implications for optimal dosing

Blood

Volumn 110, Issue 10, 2007, Pages 3552-3556

  Klion, Amy D ^a,c   Robyn, Jamie ^a,b   Maric, Irina ^c   Fu, Weiming ^c   Schmid, Laura ^a   Lemery, Steven ^b   Noel, Pierre ^c   Law, Melissa A ^a   Hartsell, Marilyn ^a   Talar Williams, Cheryl ^a   Fay, Michael P ^a   Dunbar, Cynthia E ^b   Nutman, Thomas B ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; HYDROXYUREA; IMATINIB; INTERFERON; LISINOPRIL; MONOCLONAL ANTIBODY; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; SCH 55700; TRYPTASE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ANGIONEUROTIC EDEMA; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG WITHDRAWAL; EOSINOPHIL COUNT; EOSINOPHILIC LEUKEMIA; FOLLOW UP; HEART MUSCLE FIBROSIS; HUMAN; NEUTROPENIA; OPTIMAL DRUG DOSE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RELAPSE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 36348993783     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-07-100164     Document Type: Article

References (20)

1. Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alpha plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003;349:1423-1432.
2. Bhatia R, Holtz MS, Niu N, et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood. 2003;101:4701-4707.
3. Graham SM, Jorgensen HG, Allan E, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood. 2002;99:319-325.
4. Holtz MS, Slovak ML, Zhang F, Sawyers CL, Forman SJ, Bhatia R. Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood. 2002;99:3792-3800.
5. Chu S, Xu H, Shah NP, et al. Detection of BCRABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatiinb mesylate therapy. Blood. 2005;105:2093-2098.
6. Sherbenou DW, Wong MJ, Humayun A, et al. Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable completye cytogenetic response to imatinib. Leukemia. 2007;21:489-493.
7. Cools J, DeAngelo DJ, Gotlib J, et al. A novel tyrosine kinase created by the fusion of the PDG-FRA and FIP1L1 genes is a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348:1201-1214.
8. Klion AD, Robyn J, Akin C, et al. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood. 2003;103:473-478.
9. Pardanani A, Ketterling RP, Li CY, et al. FIP1L1/PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. Leuk Res. 2006;30:965-970.
10. Cervantes F, Hernandez-Boluda JC, Steegman JL, et al. Imatinib mesyalte therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients. Haematologica. 2003;88:1117-1122.
11. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408-2417.
12. Robyn J, Lemery S, McCoy JP, et al. Multilineage involvement of the fusion gene in patients with FIP1L1/PDGFRA-positive hypereosinophilic syndrome. Br J Haematol. 2005;132:286-292.
13. Kantarjian H, Sawyers C, Hochhaus A, al. e. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346:642-652.
14. Druker BJ, Sawyers CL, Capdeville R, Ford JM, Baccarani M, Goldman JM. Chronic myelogenous leukemia. Hematology. 2001:87-112.
15. Rousselot P, Huguet F, Rea D, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete remission for more than two years. Blood. 2007;109:58-60.
16. Cortes J, O'Brien S, Kantarjian H. Discontinuation of imatinib therapy after achieving molecular response. Blood. 2004;104:2204-2205.
17. Mauro MJ, Druker BJ, Maziarz RT. Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission. Leuk Res. 2004;28:S71-S73.
18. Merante S, Orlandi E, Bernasconi P, Calatroni S, Boni M, Lazzarino M. Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation. Haematologica. 2005;90:9790981.
19. Lee J-L, Ryu M-H, Chang HM, et al. Clinical outcome in gastrointestinal stromal tumor patients who interrupted imatinib after achieving stable disease or better response. Jpn J Clin Oncol. 2006;36:704-711.
20. Jovanovic JV, Score J, Waghorn K, et al. Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDG-FRA-positive chronic eosinophilic leukemia. Blood. 2007;109:4635-4640.